- FibroGen press release ( NASDAQ: FGEN ): Q2 GAAP EPS of -$0.78 beats by $0.19 .
- Revenue of $29.81M (+22.4% Y/Y) misses by $6.34M .
For further details see:
FibroGen GAAP EPS of -$0.78 beats by $0.19, revenue of $29.81M misses by $6.34MFor further details see:
FibroGen GAAP EPS of -$0.78 beats by $0.19, revenue of $29.81M misses by $6.34MMarket Wire News is a media platform, the information on this page was provided by SeekingAlpha via Quote Media. Read our full disclaimer.
When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
News, Short Squeeze, Breakout and More Instantly...
SAN FRANCISCO, April 24, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN) today announced that clinical data from the dose escalation porti...
SAN FRANCISCO, April 24, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that clinical data from the dose escalation portion of the Phase 1b/2 study of FG-3246 in combination with enzalutamide in patients with metastatic castration resistant prostate cancer have been select...
Shares of Ulta Beauty, Inc. (NASDAQ: ULTA) fell sharply during Wednesday’s session amid the company's presentation at the J.P. Morgan Re...